Vertex Pharmaceuticals Incorpor
VRTX
Positions held
Your positionsVRTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Vertex Pharmaceuticals is a leader in the biotechnology industry, focusing on innovative treatments for serious diseases, which positions it well against competitors.
- In Q2 2026, Vertex reported a revenue increase of 12% compared to the previous quarter, reaching $3.3 billion.
- The company's gross margin was 85.3% in Q2 2026, although it slightly decreased from 86.8% in the prior quarter.
- Despite its strong market position, Vertex faces challenges with a high debt-to-equity ratio of 9.767, indicating potential financial risk.
- In 2024, Vertex experienced a significant operating margin decline to -2.12%, resulting in a net income loss of $535.6 million.
- The stock's current recommendation is 'buy', but the overall score is neutral at 5.00, reflecting mixed market signals.
Fundamentals
| Market cap | $127.55B | Enterprise value | $121.68B | Trailing P/E | 29.31 | Forward P/E | 24.89 |
| PEG | 1.97 | Price / book | 6.30 | Beta | 0.28 | Dividend yield | 0.00% |
| Revenue growth | 12.5% | Earnings growth | 8.0% | Gross margin | 55.0% | Operating margin | 38.1% |
| Profit margin | 35.0% | ROE | 23.5% | ROA | 11.9% | Debt / equity | 0.10 |
| Current ratio | 3.19 | Free cash flow | $2.63B | Analyst recommendation | buy | Mean target | $571.61 |
| 52w high | $560.25 | 52w low | $402.58 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $3.3B | $3.0B | $3.2B | $3.1B | $3.0B | — |
| Op margin | 38.1% | 38.1% | 35.4% | 40.3% | 38.9% | — |
| Net income | $1.1B | $1.0B | $1.2B | $1.1B | $1.0B | — |
| Gross margin | 85.3% | 86.8% | 85.4% | 86.5% | 86.3% | — |
| Gross profit | $2.8B | $2.6B | $2.7B | $2.7B | $2.6B | — |
| Operating income | $1.3B | $1.1B | $1.1B | $1.2B | $1.2B | — |
- Revenue +12% vs prior quarter ($3.3B vs $3.0B).
- Gross margin 85.3% (was 86.8% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $12.0B | $11.0B | $9.9B | $8.9B | — |
| Op margin | 37.9% | -2.1% | 38.3% | 47.6% | — |
| Net income | $4.0B | -$536M | $3.6B | $3.3B | — |
| Gross margin | 86.2% | 86.1% | 87.2% | 87.9% | — |
| Gross profit | $10.3B | $9.5B | $8.6B | $7.9B | — |
| Operating income | $4.6B | -$233M | $3.8B | $4.2B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children
2026-10-09 · Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
2026-10-09 · Is Vertex Stock Worth More Than Its Competitors?
2026-10-08 · Why Pacira BioSciences Stock Is Having Its Best Day Ever After $1.7 Billion Viatris Acquisition
2026-10-08 · Andrew Hill Investment Fund Sees More Growth Ahead for Vertex (VRTX): Here’s Why
2026-10-08 · RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating
2026-10-07 · Vertex to Announce Third Quarter 2026 Financial Results November 2nd
2026-10-07 · NVIDIA And 2 Elite Undervalued Stocks To Own
2026-10-06 · Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
2026-10-05 · Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
2026-10-05 · Vortex Energy Commissions Hydrogen and Helium Study at Robinsons River Salt Project
2026-10-05 · 2 Safe-and-Steady Stocks with Promising Prospects and 1 We Turn Down
Price (daily)
Full chart · RSI · MACD · patterns